

## **Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-Like Illness in Healthcare Workers: A Randomized Clinical Trial**

Noud van Helmond MD PhD,<sup>1</sup> Tracy L. Brobyn MD,<sup>2,3,4,5</sup> Patrick J. LaRicca MD MSCE,<sup>4,6</sup> Teresa Cafaro BS, CRA, CRC<sup>1,4,7</sup> Krystal Hunter PhD MBA,<sup>2,7</sup> Satyajeet Roy MD FACP,<sup>2,8</sup> Brigid Bandomer RN, BSN,<sup>4</sup> Kevin Q. Ng MD,<sup>3,4,9</sup> Helen Goldstein BSN, CRA,<sup>4</sup> Ludmil V. Mitrev MD,<sup>1,2</sup> Alan Tsai BA,<sup>2</sup> Denise Thwing RN, BSN, MAS, CEN,<sup>4</sup> Mary Ann Maag RN, BSN, CCRA,<sup>4</sup> Myung K. Chung MD<sup>2,3,4,10</sup>

### **From the**

<sup>1</sup>Department of Anesthesiology, Cooper University Health Care, Camden, NJ, USA

<sup>2</sup>Cooper Medical School of Rowan University, Camden, NJ, USA

<sup>3</sup>The Chung Institute of Integrative Medicine, Moorestown, NJ, USA

<sup>4</sup>Won Sook Chung Foundation, Moorestown, NJ, USA

<sup>5</sup>Rowan University School of Osteopathic Medicine, Stratford, NJ, USA

<sup>6</sup>Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA

<sup>7</sup>Cooper Research Institute, Cooper University Health Care, Camden, NJ, USA

<sup>8</sup>Division of General Internal Medicine, Cooper University Health Care, Camden, NJ, USA

<sup>9</sup>Department of Medicine, Cooper University Health Care, Camden, NJ, USA

<sup>10</sup>Department of Family Medicine, Cooper University Health Care, Camden, NJ, USA

### **Address correspondence to:**

Ludmil V. Mitrev, One Cooper Plaza, Camden, NJ 08103, USA, (e-mail: [mitrev-ludmil@cooperhealth.edu](mailto:mitrev-ludmil@cooperhealth.edu))

Noud van Helmond, One Cooper Plaza, Camden, NJ 08103, USA, (e-mail: [vanhelmond-noud@cooperhealth.edu](mailto:vanhelmond-noud@cooperhealth.edu))

### **Running Head:**

Vitamin D supplementation in healthcare workers

### **Word count:**

Abstract: 378

Manuscript: 3887

### **Table count:** 4

### **Figure count:** 4

**Keywords:** vitamin D, COVID-19, influenza-like illness, healthcare workers, hospital workers, randomized clinical trial

**Abbreviations:** COVID-19 = coronavirus disease 2019; ILI = influenza-like illness

## Key Points

**Question:** Can 5,000 IU of daily vitamin D3 prevent influenza-like illness in healthcare workers?

**Findings:** In this randomized controlled trial, 5,000 IU of once daily vitamin D3 over a 9-month period revealed that vitamin D3 supplementation was associated with a statistically significant lower risk of influenza-like illness (incidence rate difference  $-1.7 \times 10^{-4}$  / person-day, 95%-CI -  $3.0 \times 10^{-4}$  to  $-3.3 \times 10^{-5}$  / person-day,  $P = 0.0147$ ).

**Meaning:** Daily supplementation with 5,000 IU vitamin D3 reduces influenza-like illness in healthcare workers.

## ABSTRACT

**Importance:** Vitamin D supplementation has been shown to reduce the incidence of acute respiratory infections in populations at risk. The COVID-19 pandemic has highlighted the importance of preventing viral infections in healthcare workers.

**Objective:** The aim of this study was to assess the hypothesis that vitamin D3 supplementation at 5000 IU daily reduces influenza-like illness (ILI), including COVID-19, in healthcare workers.

**Design:** We conducted an open label, randomized clinical trial wherein a random group of healthcare workers was invited to receive 5000 IU daily vitamin D3 supplementation for nine months, while other random healthcare workers served as passive controls. All healthcare workers were required to self-monitor and report to employee health for COVID-19 testing when experiencing symptoms of ILI. COVID-19 test results were retrieved.

**Setting:** The trial was conducted at a tertiary university hospital.

**Participants:** Out of 7,600 healthcare workers, two groups of 4,708 and 2,892 subjects were pre-randomized to the vitamin D3 intervention and passive control groups, respectively. Out of 4,708 intervention subjects approached, 299 with no history of hypercalcemia or nephrolithiasis were enrolled. Subjects who completed at least 2 months of supplementation to ensure adequate vitamin D levels were included in the analysis (n=255).

**Intervention:** Daily oral vitamin D3 gel capsules at 5000 IU for 9 months.

**Main Outcome and Measure:** The primary analysis compared the incidence rate of all ILI, while secondary analyses examined incidence rates of COVID-19 ILI and non-COVID-19 ILI. Incidence rates were compared between the vitamin D and control groups.

**Results:** Between October 2020 and November 2021, 255 healthcare workers (age  $47 \pm 12$  years, 199 women) completed at least two months of vitamin D3 supplementation. Five subjects were withdrawn due to adverse effects. The control group consisted of 2,827 workers. Vitamin D3 5000 IU supplementation was associated with lower risk of ILI (incidence rate difference:  $-1.7 \times 10^{-4}$ /person-day, 95%-CI:  $-3.0 \times 10^{-4}$  to  $-3.3 \times 10^{-5}$ /person-day,  $P = 0.015$ ) and a lower incidence rate for non-COVID-19 ILI (incidence rate difference:  $-1.3 \times 10^{-4}$ /person-day, 95%-CI  $-2.5 \times 10^{-4}$  to  $-7.1 \times 10^{-6}$ /person-day,  $P = 0.038$ ). COVID-19 ILI incidence was not statistically different (incidence rate difference:  $-4.2 \times 10^{-5}$ /person-day, 95%-CI:  $-10.0 \times 10^{-5}$  to  $1.5 \times 10^{-5}$ /person-day,  $P = 0.152$ ). An intention-to-treat analysis could not be performed due to low enrollment in the pre-randomized intervention group.

**Conclusion and Relevance:** Daily supplementation with 5000 IU vitamin D3 reduces influenza-like illness in healthcare workers.

**Trial Registration:** Clinicaltrials.gov, NCT04596657

## INTRODUCTION

Healthcare workers are frequently affected by acute respiratory tract infections<sup>1</sup> and have a higher risk of acquiring coronavirus disease 2019 (COVID-19) than the general population.<sup>2</sup> In addition to the individual disease burden to sick workers, the potential pathogen transmission by sick workers creates a serious patient safety concern.<sup>3,4</sup> Furthermore, illness in hospital workers has often created staffing shortages in vital positions in the current COVID-19 pandemic.<sup>5</sup>

Outside the COVID-19-specific literature, meta-analyses have found that vitamin D supplementation taken over weeks to months reduces acute respiratory infections.<sup>6-8</sup> This effect is more pronounced in individuals with the lowest baseline serum concentrations of vitamin D, but remains significant independent of baseline levels.<sup>6-8</sup> Importantly, the protective effect is more pronounced when vitamin D is supplemented in daily doses, when compared to large boluses.<sup>6-8</sup> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters human cells through cell surface angiotensin-converting enzyme 2 receptors.<sup>9</sup> Inadequate blood concentrations of vitamin D are associated with inappropriate activation of the renin-angiotensin-aldosterone system.<sup>10</sup> This mechanistic link between vitamin D concentrations and COVID-19's pathophysiology, combined with the body of evidence supporting vitamin D supplementation as a method to reduce other respiratory tract infections, led to calls for prospective clinical studies on vitamin D supplementation for COVID-19.<sup>11</sup>

Early in the COVID-19 pandemic, prospective clinical trials on vitamin D supplementation for COVID-19 assessed if vitamin D could ameliorate the clinical course in patients with various levels of COVID-19 severity. Repeated high-dose vitamin D supplementation improved viral clearance in asymptomatic or mildly symptomatic patients,<sup>12</sup> as well as reduced the need for intensive care unit treatment in hospitalized patients.<sup>13</sup> However, a single high-dose of vitamin D

did not reduce hospital length of stay in hospitalized patients with moderate to severe COVID-19.<sup>14</sup> While the pre-COVID evidence for an effect of vitamin D on respiratory tract infection is found predominantly in preventing acute disease,<sup>6-8</sup> prospective studies on vitamin D supplementation for COVID-19 prevention have been absent. Two recent studies by Jolliffe et al. and Vallasis et al. had conflicting results.<sup>15,16</sup>

The aims of this study were to assess if daily vitamin D can prevent non-COVID-19 and COVID-19 related influenza-like illness (ILI) in healthcare workers. During the COVID-19 pandemic, healthcare workers in our hospital were required to self-monitor for symptoms of ILI and report to our employee health service for COVID-19 testing. We hypothesized that daily vitamin D3 supplementation in healthcare workers leads to reduced incidence of ILI due to reduction of both non-COVID-19 ILI and COVID-19 ILI when compared to other healthcare workers.

## METHODS

### *Subjects and regulatory approval*

Starting in October 2020, and over the course of 13 months, we conducted a prospective study (Clinicaltrials.gov: NCT04596657) in healthcare workers to investigate two aims: 1. To assess if daily vitamin D3 can prevent ILI in healthcare workers; 2. To assess if daily vitamin D can prevent COVID-19 in healthcare workers. A randomly selected group of healthcare system employees were approached for participation in the study to take daily vitamin D3 supplementation for nine months. Workers aged 18 years or older were eligible to participate; exclusion criteria consisted of conditions or medications and supplements that could increase health risk by receiving vitamin D supplementation (Table 1). All participants provided written informed consent after all study information was provided in detail and an opportunity to ask questions was provided. The local Institutional Review Board approved this study (IRB #20-455). This study adhered to CONSORT guidelines.<sup>17</sup> The CONSORT checklist is included in supporting information S1.

### *Recruitment and Randomization*

Using a list of all healthcare system workers aged 18 years or older, we randomized workers to the intervention (vitamin D3) and control groups (Figure 1). We used a Zelen's design<sup>18-22</sup> for this study, which is a pragmatic clinical trial design whereby subjects are randomized prior to informed consent, and wherein initially only subjects randomized to the interventional arm are approached for consent and subsequently enrolled. Our initial intention was to enroll only subjects aged 52 and older with 1:1 randomization between the groups. Our calculated sample

size for a power of 85% was based on previous influenza-like illness occurrences in our healthcare workers. This resulted in a sample size requirement of 859 subjects. Early in the trial it became apparent that recruitment was low, thus the lower limit of age for eligibility to participate in the trial was changed from 52 to 18.

Randomization was performed by the biostatistician and a co-investigator utilizing the RAND function in Microsoft Excel. When the younger adults were allowed to be enrolled in the trial, we switched from 1:1 to 2:1 randomization (intervention:control). Subjects randomized to the intervention arm were contacted by email to assess their interest in receiving daily vitamin D3 supplementation. Those randomized employees interested in participating were screened for inclusion and exclusion criteria. Those in the passive control group were contacted towards the end of the study to voluntarily complete a survey which included their informed consent, medical history, vitamin D intake history, and COVID-19 vaccination history. The pragmatic design of the study was the basis for contacting control subjects toward the end of the study. Zelen's design is ethical and particularly useful within the context of trials of prevention and screening interventions.<sup>19,20,23,24</sup> A flow-diagram outlining the randomization and consent procedures is presented in Figure 1.

### *Vitamin D*

Vitamin D3 was supplied to eligible participants in oral gel capsules at a dose of 5000 IU per day (Res-Q Vital D3, N3 Oceanic Inc, Pennsburg, Pennsylvania, USA). A daily dose of 5000 IU is required to attain normal serum 25(OH)D concentrations in individuals who have concentrations below 55 nmol/L at baseline without supplementation.<sup>25</sup> Furthermore, in the state of New Jersey

where this study was conducted, 28% of adults over the age of 20 are obese,<sup>26</sup> and obese individuals require 2-3 times the normal dose of vitamin D supplementation for vitamin D deficiency.<sup>27</sup> The protective effect of vitamin D supplementation on acute respiratory tract infections that was found in systematic reviews in individuals without particularly low serum concentrations of 25(OH)D supports providing supplementation of vitamin D3 to individuals who may not be deficient in serum vitamin D by current clinical standards.<sup>6-8</sup>

Pillboxes were provided to promote adherence to vitamin D3 supplementation (Pill Thing, Inc., Ellisville, Missouri, USA). Biweekly automated text and email reminders (Twilio, San Francisco, California, USA) were used as an additional method to support adherence to the study supplementation. Emails included a picture of the vitamin D3 supplement. Vitamin D3 supplementation was provided for three months at the start of the study, and again at three and six months of study participation.

### *Survey data collection*

Using an electronic data capturing system (REDCap,<sup>28,29</sup> Vanderbilt University, Nashville, TN, USA), we collected information on demographic characteristics, medical history, vitamin D deficiency history, COVID-19 history, as well as influenza and COVID-19 vaccination status. In the intervention group, we additionally collected information on self-reported adherence to the daily vitamin D3 study supplementation. Adherence was monitored in two ways: 1. Monthly surveys asking subjects to report the number of missed doses and 2. Every three months over the 9-month study period subjects were asked on their monthly survey to count the number of pills left in their bottle which originally contained a 3-month supply.

### *Primary and secondary outcome measurement*

As part of standard employee health and patient safety procedures during the COVID-19 pandemic, all healthcare system workers were required to self-monitor daily for ILI symptoms. Symptomatic workers were required to contact employee health services. The employee health department then prescribed swab polymerase chain reaction (PCR) testing for these employees considering the possibility that these symptoms were due to COVID-19. Our primary outcome, incidence rate of ILI, was defined as workers who were referred for testing at least once during the study period. The secondary outcomes, incidence rate of COVID-19 ILI and non-COVID-19 ILI, were defined as at least 1 positive and at least 1 negative COVID-19 PCR test(s) during the study period, respectively.

### *Safety assessments*

Considering the excellent safety profile of vitamin D3 at a dose of 5000 IU/day,<sup>30-34</sup> we did not include laboratory testing or other clinical interventions in our procedures unless clinically indicated. Subjects were monitored via monthly surveys that queried subjects on symptoms of hypercalcemia and nephrolithiasis which included 15 symptoms.<sup>35</sup> In addition, subjects were asked if they had experienced any new or unusual health changes and if they were taking any new medications. If subjects indicated symptoms, health changes, or new medications, additional information was collected through open-ended questions and they were contacted by a study investigator by phone to obtain more information. Symptoms of concern were shared with the primary safety monitor (SR) who ordered laboratory tests; scheduled outpatient visits for

evaluation; or referred the subject for additional evaluation when indicated. The safety population included all individuals in the intervention group. Adverse events (AEs) were defined as treatment-emergent AEs if they occurred on or after the date of the first dose of vitamin D3 and up to the end of each subject's study period.

### *Adherence*

Supplementation adherence rates were calculated by dividing the number of pills taken by the number of pills that should have been taken. During the study subjects reported the number of pills remaining in bottles 1, 2 and 3 at survey months 3, 6 and 9, respectively. The total adherence calculation for subjects with complete adherence data is the sum of pills taken at months 3, 6 and 9 (days 90, 180 and 270) divided by 270 (i.e., sum of pills in bottles 1, 2 and 3). Withdrawn subjects were included, as well as subjects who had periods of vitamin D3 interruption. In these cases, the denominator was adjusted accordingly. Any subjects with missing adherence data (i.e., missing pill counts at months 3, 6 or 9) or incongruent data were not included in the adherence calculation.

### *Data & Statistical Analysis*

Characteristics of the intervention and control group are presented as mean  $\pm$  standard deviation or n (%). Workers in the intervention group were included in the analysis if they completed at least 2 months of supplementation, to allow for adequate vitamin D plasma levels.<sup>25</sup> Workers who discontinued supplementation after at least 2 months of supplementation were included up to the time of discontinuation or termination of employment. To provide an objective means to

identify meaningful differences in demographic and clinical characteristics between the intervention and control groups we used standardized mean differences with a cutoff of 20% or 0.20<sup>36,37</sup>, see Table 2. Because our resulting sample size was suboptimal (70.3% short of targeted sample size), we conducted a per protocol analysis; an intention to treat analysis would require all of the subjects who did not elect to participate to be calculated as part of the intervention group. To achieve the study aims, we compared the incidence rate of all ILI determined by PCR testing for COVID-19 conducted by employee health in the intervention and control group subjects. The incidence rate was expressed as workers who had experienced at least 1 ILI (positive or negative SARS-COV-2 PCR test results). Separate analyses were performed for the incidence rate of COVID-19 ILI (positive SARS-COV-2 PCR test results) and non-COVID-19 ILI (negative SARS-COV-2 PCR test results). Confidence intervals of the difference in rates were calculated using the “Test Base Method” and P-values were obtained using the Chi-square statistic.<sup>38</sup> To assess the influence of COVID-19 vaccination, secondary analyses were performed on incidence rates including only the observation period after a worker was fully vaccinated (14 days after the second dose of an mRNA vaccine<sup>39,40</sup> or after the first dose of the non-mRNA Ad26.COV2.S vaccine<sup>41</sup>). MedCalc (version 20, MedCalc Software Ltd, Ostend, Belgium) was used for all statistical analyses and Prism (version 9, GraphPad Software Inc, San Diego, CA, USA) was used to create graphs.

## RESULTS

### *Trial enrollment and baseline characteristics*

Of our targeted sample size of 859 subjects, 299 healthcare system workers were enrolled between October 27, 2020 and January 31, 2021 to participate in the intervention group. A total of 255 subjects completed vitamin D3 supplementation for at least 2 months and were included in the analyses. The last study participant completed nine months of vitamin D3 supplementation on November 23, 2021. During the same period, 2,892 random healthcare system employees were passively enrolled to constitute the control group. Five hundred and seventy-eight control group participants provided demographic and clinical information at the completion of the study period. Detailed trial flow is presented in the CONSORT trial flowchart – Figure 1.

Demographic and clinical characteristics were similar between the vitamin D3 supplementation intervention and control groups – Table 2. Average age was slightly higher in the control group (50 vs. 47) years. Average adherence rate of vitamin D3 supplementation was 87% with a median rate of 91%.

The total observation time in the intervention and control groups was 49,147 and 861,141 person-days, respectively. The not-fully-vaccinated observation periods comprised 5,879 and 240,784 person-days in the intervention and control groups, respectively, whereas fully-vaccinated observation periods were 43,268 and 620,357 person-days.

### *All influenza-like illness*

In the intervention group, three workers had at least 1 episode of ILI, while 197 workers in the control group had at least 1 episode of ILI. Incidence rates of ILI in the vitamin D3 supplementation and control groups are presented in Table 3 and Figure 2. Comparison of incidence rates revealed that vitamin D3 supplementation was associated with a lower risk of ILI

(incidence rate difference  $-1.7 \times 10^{-4}$  / person-day, 95%-CI  $-3.0 \times 10^{-4}$  to  $-3.3 \times 10^{-5}$  / person-day,  $P = 0.0147$ ). Incidence rate differences were  $-4.653 \times 10^{-4}$  / person-day, 95%-CI  $-1.1118 \times 10^{-3}$  to  $1.811 \times 10^{-4}$  / person-day,  $P = 0.1583$  and  $-2.632 \times 10^{-5}$  / person-day, 95%-CI  $-1.0833 \times 10^{-4}$  to  $5.57 \times 10^{-5}$  / person-day,  $P = 0.5294$  when only considering non-fully-vaccinated and fully-vaccinated observation periods in participants, respectively – Table 4 and Figures 3 & 4.

### *COVID-19 influenza-like illness*

In the intervention group, no workers had a positive COVID-19 PCR test during the observation period, while in the control group 36 workers had at least 1 positive COVID-19 PCR test. Incidence rates in the vitamin D3 supplementation and control groups are presented in Table 3 and Figure 2. Comparison of incidence rates revealed that vitamin D3 supplementation was associated with a non-statistically significant lower risk of COVID-19 ILI (incidence rate difference  $-4.181 \times 10^{-5}$  /person-day, 95%-CI  $-9.897 \times 10^{-5}$  to  $1.536 \times 10^{-5}$  / person-day,  $P = 0.1517$ ). The incidence rate difference was  $-1.495 \times 10^{-4}$  /person-day, 95%-CI  $-4.621 \times 10^{-4}$  to  $1.63 \times 10^{-4}$  / person-day,  $P = 0.3485$  when only considering non-fully-vaccinated observation periods in participants; no COVID ILI occurred in either group during the fully vaccinated observation period – Table 4 and Figures 3 & 4.

### *Non-COVID-19 influenza-like illness*

In the intervention group, three workers had at least 1 episode of non-COVID-ILI, while 165 workers in the control group had at least 1 episode of non-COVID-ILI. Incidence rates of non-COVID ILI in the vitamin D supplementation and control groups are presented in Table 3 and

Figure 2. Comparison of incidence rates revealed that vitamin D supplementation was associated with a lower risk of non-COVID-ILI (incidence rate difference  $-1.306 \times 10^{-4}$  / person-day, 95%-CI  $-2.541 \times 10^{-4}$  to  $-7.1 \times 10^{-6}$  /person-day,  $P = 0.0382$ ). Incidence rate differences were  $-3.324 \times 10^{-4}$  / person-day, 95%-CI  $-9.078 \times 10^{-4}$  to  $2.43 \times 10^{-4}$  / person-day,  $P = 0.2575$  and  $-2.632 \times 10^{-5}$  /person-day, 95%-CI  $-1.0833 \times 10^{-4}$  to  $5.57 \times 10^{-5}$  / person-day,  $P = 0.5294$  when only considering non-fully-vaccinated and fully-vaccinated observation periods in participants – Table 4 and Figures 3 & 4.

### *Treatment Emergent Adverse events (TEAEs)*

Among the 299 enrolled subjects, 182 workers in the intervention group reported at least 1 TEAE(s). Out of 388 reported TEAEs, 80% were judged to be unrelated, 18% possibly related, and 2.1% probably related. See supporting information S2 for a comprehensive listing of all TEAEs. There was one unrelated serious adverse event: hospitalization due to ruptured Meckel's diverticulitis.

The 8 probably related TEAEs occurred in five participants. One participant reported 3 adverse events that began after 7 months on study vitamin D3: burning sensation in arms and legs; oral tenderness; and hypersensitivity to the sun. Interruption of vitamin D3 for 15 days showed slight improvement in symptoms. Upon resuming vitamin D3 for two weeks, the subject reported worsening of symptoms. Abatement of all symptoms was reported approximately one month after final vitamin D3 discontinuation. The subject was withdrawn from the study. One subject reported 2 adverse events after 5 weeks on vitamin D3: thirst; and frequent urination. The symptoms abated after discontinuing vitamin D3. Upon resumption, symptoms returned. The

subject was withdrawn from the study. One subject reported worsening back and right leg pain. The subject discontinued vitamin D3 after approximately 5 weeks on study due to worsening pain. Within one to two weeks of discontinuation the subject reported that pain levels returned to baseline. The subject was withdrawn from the study. One subject was on vitamin D3 for approximately two months when she developed mouth lesions. The subject stopped vitamin D3 for 1 week and the lesions resolved. Upon resuming vitamin D3 for a few days, a small lesion appeared. The subject stopped vitamin D3 and discontinued involvement with the study. One subject reported mild abdominal cramping after 10 days on vitamin D3. The subject stated the issue resolved after changing the time of day (not provided) she took vitamin D3 and the subject completed the study.

Three in-person clinic visits occurred to examine subjects for palpitations, joint pain/depression/nausea and lower back pain/leg pain. Laboratory tests (vitamin D, calcium, phosphorus, magnesium levels) were ordered for a total of 22 subjects. There were no instances of hypercalcemia reported. One subject reported nephrolithiasis on a survey 1 month after the event and was immediately withdrawn. The subject's calcium level was within normal limits and the nephrolithiasis was considered unrelated to the study vitamin D3. Two subjects were withdrawn due to pregnancy.

Consistent with our protocol's provision for privacy, adverse events were not collected in the passive control group.

### *Crossover*

Five hundred seventy-eight (20%) control group subjects responded to the near-end-of-study survey that included questions regarding vitamin D3 intake: 267 (46.2%) of the respondents did not take any vitamin D3; and 311 (53.8%) did take vitamin D3. Of the 311 subjects, 205 provided sufficient information. The mean dose of those 205 respondents was 3,034 IU with a median dose of 2,000 IU. For all respondents providing sufficient information (472) the mean dose was 1,318 IU with a median dose of 0.

## DISCUSSION

### *Principal findings*

The aim of this study was to assess the hypothesis that daily vitamin D3 supplementation reduces the incidence of ILI in healthcare workers. We found that daily vitamin D3 supplementation was associated with overall reduced ILI. Contributions to this outcome came from the differences in non-COVID-ILI incidence rates throughout the entire study period and COVID-19 ILI incidence rates during the period in which healthcare workers were not vaccinated for COVID-19. Overall, a low proportion of healthcare workers tested positive on PCR testing for COVID-19 during the study.

### *Influenza-like illness*

Our primary finding is consistent with recent large meta-analyses that have looked at the effect of vitamin D3 supplementation on the incidence of respiratory tract infections.<sup>6,7,42</sup> Joliffe et al. performed a systematic review and meta-analysis of 43 double-blinded randomized controlled trials on the protective effect of vitamin D3 supplementation on respiratory tract infections and found that supplementation reduced the risk compared to placebo with an odds ratio (OR) of 0.92 (95% CI 0.86-0.99).<sup>6</sup> They found that daily supplementation was particularly protective when they separately analyzed the studies that provided daily dosing regimens in contrast to intermittent or single dose regimens (OR 0.78, 95% CI 0.65- 0.94).

### *COVID-19 ILI*

The secondary aim of this study was to assess if daily vitamin D3 supplementation could reduce ILI due to COVID-19 in healthcare workers. We found that compared to the control group, the vitamin D3 supplementation group experienced a non-statistically significant lower rate of ILI due to COVID-19. Several early pandemic prospective therapeutic studies have explored the effect of vitamin D supplementation on disease course in COVID-19 patients. Repeated high-dose vitamin D supplementation improved viral clearance in asymptomatic or mildly symptomatic patients.<sup>12</sup> Repeated administration of vitamin D to hospitalized patients with COVID-19 reduced the need for intensive care unit treatment in hospitalized patients.<sup>13</sup> However, a randomized controlled trial that assessed if a single high dose of vitamin D3 could reduce the hospital length of stay in patients with moderate to severe COVID-19, found no effect of vitamin D compared to placebo.<sup>14</sup> Orally provided vitamin D2 or D3 needs to be hepatically converted to 1,25-dihydroxyvitamin D for biological activity. It is highly questionable if critically ill patients are able to efficiently convert vitamin D delivered in a single very large bolus dose, to active 1,25-dihydroxyvitamin D.<sup>43</sup>

More recently, a randomized controlled trial on disease prevention with vitamin D supplementation of 800 IU or 3200 IU per day for 6 months in 6,200 participants found no difference in either acute respiratory tract infections or in COVID-19 incidence.<sup>15</sup> In contrast, our study found a clear difference in any influenza like illness (ILI) incidence and a non-statistically significant reduction in COVID-19 incidence. Our study employed a larger dose of vitamin D3 (5,000 IU versus 3,200 IU). In addition, our study ensured adequate vitamin D levels by requiring 2 months of vitamin D3 intake, while Jolliffe et al obtained levels at the end of their study, leaving unknown the levels during most of the observation period.<sup>15</sup> Villasis-Keever et al. demonstrated vitamin D to be protective against COVID-19 at a dose of 4,000 IU.<sup>16</sup>

### *Clinical implications*

Daily vitamin D3 supplementation is an inexpensive and safe intervention.<sup>34</sup> The results of the present study suggest that daily vitamin D3 supplementation can be recommended to reduce the incidence of ILI in healthcare workers. Reducing ILI is important to improve health in healthcare workers,<sup>1</sup> to improve patient safety due to less exposure to sick healthcare workers,<sup>3,44</sup> and to reduce health care utilization and health care cost.<sup>45,46</sup> Our result of a Covid-19 incidence reduction that was not statistically significant points to the necessity for a sufficiently powered clinical trial. Furthermore, and in the context of the vaccinated population, it appears a large sample size will be required to determine if vitamin D supplementation can help prevent breakthrough Covid-19 infections.

### *Methodological considerations*

Several methodological considerations pertain to the present study. First, we used a Zelen randomized study design in which individuals were selected to be eligible for active study participation. From the group of selected individuals, a proportion of individuals ultimately decided to participate, which introduces the possibility of selection bias. However, we stress that the enrollment was not outcome-dependent and therefore should not bias our results unless prognosis in the intervention group differed from the control group. We compared intervention group patients to control group patients and found no significant differences between groups for a range of demographic and clinical characteristics, except for age which was slightly above the predefined standardized difference threshold (standardized difference 0.24). In conclusion, we

have no indication that enrollment biased results. Additionally, we used an unblinded pragmatic design, which could have introduced observer bias.

### *Conclusions*

Daily supplementation with 5000 IU vitamin D3 can be used to reduce influenza-like illness in healthcare workers. A sufficiently powered study to assess the reduction of Covid-19 breakthrough infections is recommended.

### **ACKNOWLEDGEMENTS**

We extend gratitude to Susan J Lamon PhD, Justin Frisby MSc, Jermaine Parker, and to the healthcare workers who participated in this study.

### *Conflicts of interest:*

The president of the Won Sook Chung Foundation, Myung K. Chung, was not involved in the study design, subject consenting, data collection and analysis, decision to publish, or preparation of the manuscript. Myung K. Chung was involved in the conceptualization of the study and review of the manuscript. Tracy Brobyn is an unaffiliated member of the Cooper University Hospital Institutional Review Board and did not participate in any final decisions, nor did she participate in any votes regarding the study.

### *Data Sharing Statement*

The datasets generated and/or analyzed during the current study are available from the corresponding author following reasonable request.

### *Funding:*

This study was supported by an unrestricted grant from the Won Sook Chung Foundation.

Funding was awarded to Cooper Health System, a New Jersey non-profit corporation. Grant

Activity # 310500749.

Vitamin D capsules were donated to the study by Res-Q, N3 Oceanic Inc, Pennsburg,

Pennsylvania, USA

## REFERENCES

1. Loef B, van Baarle D, van der Beek AJ, Sanders EAM, Bruijning-Verhagen P, Proper KI. Shift Work and Respiratory Infections in Health-Care Workers. *American journal of epidemiology*. Mar 1 2019;188(3):509-517. doi:10.1093/aje/kwy258
2. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *The Lancet Public Health*. 2020;5(9):e475-e483. doi:10.1016/S2468-2667(20)30164-X
3. Widera E, Chang A, Chen HL. Presenteeism: a public health hazard. *Journal of general internal medicine*. Nov 2010;25(11):1244-7. doi:10.1007/s11606-010-1422-x
4. Çelebi G, Pişkin N, Çelik Bekleviç A, et al. Specific risk factors for SARS-CoV-2 transmission among health care workers in a university hospital. *Am J Infect Control*. Oct 2020;48(10):1225-1230. doi:10.1016/j.ajic.2020.07.039
5. Mascha EJ, Schober P, Schefold JC, Stueber F, Luedi MM. Staffing With Disease-Based Epidemiologic Indices May Reduce Shortage of Intensive Care Unit Staff During the COVID-19 Pandemic. *Anesthesia & Analgesia*. 2020;131(1):24-30. doi:10.1213/ane.0000000000004849
6. Jolliffe DA, Camargo CA, Jr., Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from

randomised controlled trials. *The Lancet Diabetes & Endocrinology*. 2021;9(5):276-292.

doi:10.1016/S2213-8587(21)00051-6

7. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583. doi:10.1136/bmj.i6583

8. Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 2013;8(6):e65835. doi:10.1371/journal.pone.0065835

9. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature*. 2020/05/01 2020;581(7807):221-224. doi:10.1038/s41586-020-2179-y

10. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest*. Jul 2002;110(2):229-38. doi:10.1172/jci15219

11. Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients*. Apr 2020;12(4)doi:10.3390/nu12040988

12. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgraduate Medical Journal*. 2020;postgradmedj-2020-139065. doi:10.1136/postgradmedj-2020-139065
  
13. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". *J Steroid Biochem Mol Biol*. Oct 2020;203:105751. doi:10.1016/j.jsbmb.2020.105751
  
14. Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. *JAMA*. 2021;doi:10.1001/jama.2020.26848
  
15. Jolliffe DA, Holt H, Greenig M, et al. Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT). *medRxiv*. 2022:2022.03.22.22271707. doi:10.1101/2022.03.22.22271707
  
16. Villasis-Keever MA, López-Alarcón MG, Miranda-Novales G, et al. Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. *Archives of Medical Research*. 2022/06/01/ 2022;53(4):423-430. doi:<https://doi.org/10.1016/j.arcmed.2022.04.003>

17. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Bmj*. Mar 23 2010;340:c332. doi:10.1136/bmj.c332
  
18. Zelen M. A new design for randomized clinical trials. *N Engl J Med*. 1979/05// 1979;300(22):1242-1245. doi:10.1056/nejm197905313002203
  
19. Torgerson DJ, Roland M. What is Zelen's design? *Bmj*. Feb 21 1998;316(7131):606. doi:10.1136/bmj.316.7131.606
  
20. Torgerson D. The use of Zelen's design in randomised trials. *Bjog*. Jan 2004;111(1):2. doi:10.1111/j.1471-0528.2004.00033.x
  
21. House A, Knapp P. Informed consent. Trials that use Zelen's procedure should be acceptable. *Bmj*. Jul 26 1997;315(7102):251.
  
22. Adamson J, Cockayne S, Puffer S, Torgerson DJ. Review of randomised trials using the post-randomised consent (Zelen's) design. *Contemp Clin Trials*. Aug 2006;27(4):305-19. doi:10.1016/j.cct.2005.11.003
  
23. Gabbard J, Pajewski NM, Callahan KE, et al. Advance care planning for vulnerable older adults within an Accountable Care Organization: study protocol for the IMPACT randomised controlled trial. *BMJ Open*. Dec 15 2019;9(12):e032732. doi:10.1136/bmjopen-2019-032732

24. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet*. Nov 30 1996;348(9040):1472-7.  
doi:10.1016/s0140-6736(96)03386-7
  
25. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. *Am J Clin Nutr*. Jun 2008;87(6):1952-8.  
doi:10.1093/ajcn/87.6.1952
  
26. New Jersey State Health Assessment Data 2020 (2020).
  
27. Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. *PLoS One*. 2014;9(11):e111265.  
doi:10.1371/journal.pone.0111265
  
28. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. Jul 2019;95:103208.  
doi:10.1016/j.jbi.2019.103208
  
29. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. Apr 2009;42(2):377-81.  
doi:10.1016/j.jbi.2008.08.010

30. Pepper KJ, Judd SE, Nanes MS, Tangpricha V. Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. Mar 2009;15(2):95-103. doi:10.4158/ep.15.2.95
  
31. Kimball SM, Mirhosseini N, Holick MF. Evaluation of vitamin D3 intakes up to 15,000 international units/day and serum 25-hydroxyvitamin D concentrations up to 300 nmol/L on calcium metabolism in a community setting. *Dermato-endocrinology*. 2017;9(1):e1300213. doi:10.1080/19381980.2017.1300213
  
32. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. *The American Journal of Clinical Nutrition*. 2007;85(1):6-18. doi:10.1093/ajcn/85.1.6
  
33. Vieth R. Vitamin D toxicity, policy, and science. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. Dec 2007;22 Suppl 2:V64-8. doi:10.1359/jbmr.07s221
  
34. Holick MF. Vitamin D Is Not as Toxic as Was Once Thought: A Historical and an Up-to-Date Perspective. *Mayo Clinic Proceedings*. 2015;90(5):561-564. doi:10.1016/j.mayocp.2015.03.015
  
35. Mayo Clinic. Hypercalcemia. Accessed 6/27/2022, 2022. <https://www.mayoclinic.org/diseases-conditions/hypercalcemia/symptoms-causes/syc-20355523>

36. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med*. Nov 10 2009;28(25):3083-107. doi:10.1002/sim.3697
  
37. Cohen J. *Statistical power analysis for the behavioral sciences*. Routledge; 2013.
  
38. Sahai H KA. *Statistics in epidemiology: methods, techniques, and applications*. CRC Press, INC; 1996.
  
39. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  
40. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. Dec 31 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  
41. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. Jun 10 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
  
42. Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLOS ONE*. 2013;8(6):e65835. doi:10.1371/journal.pone.0065835

43. Leaf DE, Ginde AA. Vitamin D3 to Treat COVID-19: Different Disease, Same Answer. *JAMA*. 2021;doi:10.1001/jama.2020.26850
44. Kinman G, Grant C. Presenteeism during the COVID-19 pandemic: risks and solutions. *Occupational medicine (Oxford, England)*. Nov 18 2020;doi:10.1093/occmed/kqaa193
45. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. *Pharmacoeconomics*. 2008;26(11):911-24. doi:10.2165/00019053-200826110-00004
46. Tsai Y, Zhou F, Kim IK. The burden of influenza-like illness in the US workforce. *Occupational medicine (Oxford, England)*. Jul 2014;64(5):341-7. doi:10.1093/occmed/kqu022

## FIGURE LEGENDS

### Figure 1.

\*Out of 299 intervention subjects, 44 subjects were excluded from analysis because they were not on 5,000 IU vitamin D3 per day for at least 60 days, a timeframe that is considered to be protective.<sup>25</sup> The resulting 255 subjects included subjects who completed the 9-month study period and early withdrawals.

\*\* Employee Health was unable to locate 27 control subject records for unknown reasons. A possibility for missing records could be due to name changes over the course of the study. Another 38 control subjects were found to have been terminated from employment prior to the study observation period and were excluded from analyses ( $n = 2,892 - 27 - 38 = 2,827$ ).

### Figure 2.

95% confidence intervals are based on the methods described by Sahai and Khurshid.<sup>38</sup> \* $P < 0.05$ .

### Figure 3.

95% confidence intervals are based on the methods described by Sahai and Khurshid.<sup>38</sup>

### Figure 4.

95% confidence intervals are based on the methods described by Sahai and Khurshid.<sup>38</sup> The upper end of the confidence interval is not visible in the figure because it is very close to zero.

**Table 1. Exclusion criteria**

- History of hypercalcemia
- History of nephrolithiasis
- History of intolerance to vitamin D3 supplements
- Use of calcium at a dose > 600 mg/day (individuals using a dose greater than 600 mg of calcium per day were asked to limit the amount to 600 mg unless they had been directed by their physician to take more than 600 mg/day. If the latter was true the potential subject was excluded from the study.)
- Use of vitamin D at a daily dose > 5000 IU\*
- Use of aluminum-containing phosphate binders in patients with renal failure
- Use of calcipotriene
- Use of digoxin
- Use of thiazide diuretics if using:
  - hydrochlorothiazide at a daily dose > 37.5 mg
  - indapamide at a daily dose > 1.25 mg
  - chlorthalidone at a daily dose > 12.5 mg
  - metolazone at a daily dose > 2.5 mg
  - methyclothiazide at a daily dose > 2.5 mg
  - chlorothiazide at a daily dose > 250 mg
  - metolazone at a daily dose > 0.5 mg
  - bendroflumethiazide at a daily dose > 2.5 mg
  - polythiazide at a daily dose > 1 mg
  - hydroflumethiazide at a daily dose > 25 mg
- Conditions that are associated with a risk of modified vitamin D metabolism
- Known allergy to wool
- Current enrollment in another study
- Life expectancy <1 month at time of screening
- Inability to provide informed consent
- Pregnant or trying to become pregnant
- Employee is team member on the present study

\*If potential participants were found to be using vitamin D supplementation upon screening at a daily dose ≤5000 IU/day, they were eligible for participation by switching to the study dose. If potential participants were taking a multiple vitamin or calcium supplement and there was less than or equal to 800 IU vitamin D in it, they could continue the multivitamin or calcium supplement along with taking the study vitamin D3. Total vitamin D could not exceed 5,800 IU per day combined between any supplements that contained vitamin D. Use of vitamin D at a daily dose > 5000 IU at the direction of a physician was an exclusion criterion. If a potential subject used over-the-counter vitamin D not directed by a physician at a daily dose > 5000 IU, they were eligible to participate by switching to the lower study dose.

**Table 2. Demographic and clinical characteristics of the vitamin D supplementation and control groups**

|                                                      | Vitamin D3<br>(n = 299) | Control<br>(n=578) | Standardized<br>difference |
|------------------------------------------------------|-------------------------|--------------------|----------------------------|
| Age at enrollment in years, mean $\pm$ SD            | 47 $\pm$ 12             | 50 $\pm$ 13        | 0.24                       |
| Gender, n (%)                                        |                         |                    |                            |
| Man                                                  | 55 (22)                 | 131 (23)           | 0.12                       |
| Woman                                                | 199 (78)                | 446 (77)           | 0.02                       |
| Other                                                | 1 (0.4)                 | 1 (0.2)            | 0.45                       |
| Race, n (%)                                          |                         |                    |                            |
| American Indian/Alaska Native                        | 1 (0.4)                 | 1 (0.2)            | 0.45                       |
| Asian                                                | 12 (5)                  | 36 (6)             | 0.04                       |
| Black/African American                               | 27 (11)                 | 47 (8)             | 0.10                       |
| Native Hawaiian/other Pacific Islander               | 2 (0.8)                 | 0 (0)              | 0.42                       |
| White                                                | 194 (76)                | 456 (79)           | 0.07                       |
| More than one race                                   | 7 (3)                   | 20 (4)             | 0.05                       |
| Other                                                | 12 (5)                  | 18 (3)             | 0.10                       |
| Ethnicity, n (%)                                     |                         |                    |                            |
| Hispanic or Latino                                   | 24 (9)                  | 28 (5)             | 0.16                       |
| Not Hispanic or Latino                               | 231 (91)                | 547 (95)           | 0.16                       |
| Body mass index in kg/m <sup>2</sup> , mean $\pm$ SD | 30 $\pm$ 6              | 29 $\pm$ 6         | 0.17                       |
| Comorbidities, n (%) <sup>b</sup>                    |                         |                    |                            |
| Cardiovascular disease                               | 60 (24)                 | 157 (27)           | 0.07                       |
| Respiratory disease                                  | 47 (18)                 | 106 (18)           | 0                          |
| Eye disease                                          | 11 (4)                  | 16 (3)             | 0.05                       |
| Gastrointestinal disease                             | 97 (38)                 | 213 (37)           | 0.02                       |
| Urological disease                                   | 19 (8)                  | 62 (11)            | 0.02                       |
| Liver disease                                        | 3 (1)                   | 8 (1)              | 0.10                       |
| Hematological disease                                | 27 (11)                 | 51 (9)             | 0                          |
| Dermatological disease                               | 42 (17)                 | 76 (13)            | 0.07                       |
| Diabetes                                             | 14 (6)                  | 44 (8)             | 0.11                       |
| Endocrine disease (other)                            | 38 (15)                 | 77 (13)            | 0.08                       |
| Malignant disease                                    | 15 (6)                  | 33 (6)             | 0                          |
| History of vitamin D deficiency, n (%)               | 62 (24)                 | 174 (30)           | 0.14                       |


**Table 3. Primary and secondary outcomes**

| <b>Illness</b>                                                                                                                                         | Intervention Group<br>Incidence Rate | Control Group<br>Incidence Rate | Incidence Rate Difference | 95%-CI                                            | <i>P</i> -value | Relative Incidence Rate | 95%-CI                                           | <i>P</i> -value |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------|---------------------------|---------------------------------------------------|-----------------|-------------------------|--------------------------------------------------|-----------------|
| <b>All ILI</b>                                                                                                                                         | $6.104 \times 10^{-5}$               | $2.288 \times 10^{-4}$          | $-1.677 \times 10^{-4}$   | $-3.025 \times 10^{-4}$ to $-3.3 \times 10^{-5}$  | 0.0147          | $2.668 \times 10^{-1}$  | $5.456 \times 10^{-2}$ to $7.913 \times 10^{-1}$ | 0.0060          |
| <b>COVID-19 ILI</b>                                                                                                                                    | 0.0                                  | $4.181 \times 10^{-5}$          | $-4.181 \times 10^{-5}$   | $-9.897 \times 10^{-5}$ to $1.536 \times 10^{-5}$ | 0.1517          | N/A                     | N/A                                              | N/A             |
| <b>Non-COVID-19 ILI</b>                                                                                                                                | $6.104 \times 10^{-5}$               | $1.916 \times 10^{-4}$          | $-1.306 \times 10^{-4}$   | $-2.541 \times 10^{-4}$ to $-7.1 \times 10^{-6}$  | 0.0382          | $3.186 \times 10^{-1}$  | $6.503 \times 10^{-2}$ to $9.474 \times 10^{-1}$ | 0.0229          |
| Incidence rates are per person-day and relative incidence rate uses control group as reference; CI - Confidence Interval; ILI - Influenza-Like Illness |                                      |                                 |                           |                                                   |                 |                         |                                                  |                 |


**Table 4. Outcomes by vaccination status observation period**

| <b>Not fully vaccinated<br/>observation period</b>                                                                                                     | Intervention<br>Group<br>Incidence<br>Rate | Control<br>Group<br>Incidence<br>Rate | Incidence<br>Rate<br>Difference | 95%-CI                                                | P-value | Relative<br>Incidence<br>Rate | 95%-CI                                            | P-value |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------|---------------------------------|-------------------------------------------------------|---------|-------------------------------|---------------------------------------------------|---------|
| <b>All ILI</b>                                                                                                                                         | $1.701 \times 10^{-4}$                     | $6.354 \times 10^{-4}$                | $-4.653 \times 10^{-4}$         | $-1.1118 \times 10^{-3}$ to<br>$1.811 \times 10^{-4}$ | 0.1583  | $2.677 \times 10^{-1}$        | $6.734 \times 10^{-3}$ to<br>$1.5139 \times 10^0$ | 0.1403  |
| <b>COVID-19 ILI</b>                                                                                                                                    | 0.0                                        | $1.495 \times 10^{-4}$                | $-1.495 \times 10^{-4}$         | $-4.621 \times 10^{-4}$ to<br>$1.63 \times 10^{-4}$   | 0.3485  | N/A                           | N/A                                               | N/A     |
| <b>Non-COVID-19 ILI</b>                                                                                                                                | $1.701 \times 10^{-4}$                     | $5.025 \times 10^{-4}$                | $-3.324 \times 10^{-4}$         | $-9.078 \times 10^{-4}$ to<br>$2.43 \times 10^{-4}$   | 0.2575  | $3.385 \times 10^{-1}$        | $8.500 \times 10^{-3}$ to<br>$1.9219 \times 10^0$ | 0.2624  |
| <b>Fully vaccinated<br/>observation period</b>                                                                                                         | Intervention<br>Group<br>Incidence<br>Rate | Control<br>Group<br>Incidence<br>Rate | Incidence<br>Rate<br>Difference | 95%-CI                                                | P-value | Relative<br>Incidence<br>Rate | 95%-CI                                            | P-value |
| <b>All ILI</b>                                                                                                                                         | $4.622 \times 10^{-5}$                     | $7.254 \times 10^{-5}$                | $-2.632 \times 10^{-5}$         | $-1.0833 \times 10^{-4}$ to<br>$5.57 \times 10^{-5}$  | 0.5294  | $6.372 \times 10^{-1}$        | $7.488 \times 10^{-2}$<br>to $2.4395 \times 10^0$ | 0.5809  |
| <b>COVID-19 ILI</b>                                                                                                                                    | 0.0                                        | 0.0                                   | 0.0                             | 0.0 to<br>$1.0 \times 10^{-4}$                        | -       | N/A                           | N/A                                               | N/A     |
| <b>Non-COVID-19 ILI</b>                                                                                                                                | $4.622 \times 10^{-5}$                     | $7.254 \times 10^{-5}$                | $-2.632 \times 10^{-5}$         | $-1.0833 \times 10^{-4}$ to<br>$5.57 \times 10^{-5}$  | 0.5294  | $6.372 \times 10^{-1}$        | $7.488 \times 10^{-2}$<br>to $2.4395 \times 10^0$ | 0.5809  |
| Incidence rates are per person-day and relative incidence rate uses control group as reference; CI - Confidence Interval; ILI - Influenza-Like Illness |                                            |                                       |                                 |                                                       |         |                               |                                                   |         |


Figure 1. CONSORT trial flowchart




**Figure 2. Incidence rate of influenza-like illness, COVID-19, and non-COVID-19 influenza-like illness in the vitamin D supplementation and control groups.**



**Figure 3. Incidence rate of influenza-like illness, COVID-19, and non-COVID-19 influenza-like illness in the vitamin D supplementation and control groups during COVID-19-non-vaccinated observation time.**



**Figure 4. Incidence rate of influenza-like illness, COVID-19, and non-COVID-19 influenza-like illness in the vitamin D supplementation and control groups during COVID-19-vaccinated observation time.**



## **SUPPORTING INFORMATION**

### **S1. CONSORT Checklist**

### **S2. Adverse events (AE) and relatedness among intervention group during 9-month study period**